HBsAg不可测的HCC患者中HBV DNA整合率高且多无肝硬化
研究纳入110例HBsAg阴性患者(90例HCC,20例无HCC),检测肝组织HBV DNA、cccDNA及整合。HCC组OBI检出率69%(62/90)高于无HCC组15%(3/20)(P < .0001);43例HCC伴OBI患者中69%有HBV DNA整合,其中91%(39/43)无肝硬化。
要点
- HBsAg阴性HCC患者中OBI检出率达69%(62/90),显著高于无HCC者的15%(3/20)(P < .0001)。
- HCC伴OBI患者中69%(43/62)存在HBV DNA整合,整合位点邻近TERT、KMT2B、CCNA2等致癌基因。
- 43例HBV DNA整合患者中91%(39/43)无肝硬化。
核心结论
- HBsAg阴性HCC患者中约70%存在OBI,其中约70%有HBV DNA整合入肝细胞DNA,且90%无肝硬化。
- HBV DNA整合位点邻近肝致癌基因,这些整合可能促进肝癌发生。
研究设计与样本
- 收集2002年11月至2017年7月香港110例HBsAg阴性患者(90例HCC,20例无HCC)的临床信息与肝组织,行肝切除或肝活检。
- 中位手术切除年龄64.1岁,中位活检采集年龄48.6岁。
- 用PCR分析并定量肝组织HBV DNA和cccDNA,用Alu-PCR检测HBV DNA整合。
主要发现
- 90例HBsAg阴性HCC患者中,酒精性肝病18例(20%),NAFLD/NASH 14例(16%),原发性胆汁性胆管炎2例,复发性化脓性胆管炎2例,自身免疫性肝炎1例,无上述疾病53例(59%)。
- 20例无HCC患者中,NAFLD/NASH 7例,原发性胆汁性胆管炎7例,自身免疫性肝炎6例。
- OBI在HCC组检出62/90(69%),无HCC组检出3/20(15%)(P < .0001)。
- HCC伴OBI患者中,cccDNA可检出29/62(47%),HBV DNA整合检出43/62(69%);3例无HCC的OBI患者未检出cccDNA和整合。
- 肝组织cccDNA不可测的33例中29例(88%)有整合,cccDNA可测的29例中14例(48%)有整合(P = .001)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In some individuals with undetectable serum levels of hepatitis B surface antigen (HBsAg), hepatitis B virus (HBV) DNA can still be detected in serum or hepatocytes and HBV replicates at low levels-this is called occult HBV infection (OBI). OBI has been associated with increased risk of hepatocellular carcinoma (HCC). We investigated the incidence of OBI in patients with HCC and other liver diseases. We also investigated whether, in patients with OBI and HCC, HBV DNA has integrated into the DNA of hepatocytes. METHODS: We collected clinical information and liver tissues from 110 HBsAg-negative patients (90 with HCC and 20 without HCC; median ages at surgical resection and biopsy collection, 64.1 and 48.6 years, respectively) who underwent liver resection or liver biopsy from November 2002 through July 2017 in Hong Kong. HBV DNA and covalently closed circular DNA (cccDNA) were analyzed and quantified by PCR in liver tissues. Integration of HBV DNA into the DNA of liver cells was detected by Alu-PCR. RESULTS: Of the 90 HBsAg-negative patients with HCC, 18 had alcoholic liver disease (20%), 14 had non-alcoholic fatty liver disease or steatohepatitis (16%), 2 had primary biliary cholangitis, 2 had recurrent pyogenic cholangitis, 1 had autoimmune hepatitis, and 53 had none of these (59%). Among the 20 patients without HCC, 7 had non-alcoholic fatty liver disease or steatohepatitis, 7 had primary biliary cholangitis, and 6 had autoimmune hepatitis. OBI was detected in 62/90 patients with HCC (69%) and 3/20 patients without HCC (15%) (P < .0001). cccDNA was detectable in liver cells of 29 patients with HCC and OBI (47%) and HBV DNA had integrated into DNA of liver cells of 43 patients with HCC and OBI (69%); cccDNA and integrated HBV DNA were not detected in the 3 patients who had OBI without HCC. There were 29 patients with integration of HBV DNA among 33 patients with undetectable cccDNA in liver tissues (88%) and 14 patients with integration of HBV DNA among the 29 patients with cccDNA in liver tissues (48%) (P = .001). HBV DNA was found to integrate near genes associated with hepatocarcinogenesis, such as those encoding telomerase reverse transcriptase, lysine methyltransferase 2B, and cyclin A2. Among the 43 patients with integration of HBV DNA, 39 (91%) did not have cirrhosis. CONCLUSIONS: In an analysis of clinical data and liver tissues from 90 HBsAg-negative patients with HCC, we found that almost 70% had OBI, of whom 70% had integration of HBV DNA into liver cell DNA; 90% of these patients did not have cirrhosis. HBV DNA integrated near hepatic oncogenes; these integrations might promote development of liver cancer.
引用
- Wong DK, Cheng SCY, Mak LL, et al. Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. Clin Gastroenterol Hepatol. 2019. PMID: 31252193. doi:10.1016/j.cgh.2019.06.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。